ZyVersa Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZVSA research report →
About the company
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease.
- CEO
- Stephen C. Glover
- IPO
- 2022
- Employees
- 7
- HQ
- Weston, FL, US
Price Chart
- Market Cap
- $1.16M
- P/E
- -0.04
- P/S
- 0.00
- P/B
- -81.97
- EV/EBITDA
- -36.92
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 58.55%
- ROIC
- -16.53%
- Revenue
- $0 · 0.00%
- Net Income
- $-24,952,378 · 99.73%
- EPS
- $-4.18 · 50.71%
- Op Income
- $-6,844,787
- FCF YoY
- 32.35%
- 52W High
- $1.67
- 52W Low
- $0.11
- 50D MA
- $0.19
- 200D MA
- $0.18
- Beta
- 0.81
- Avg Volume
- 12.63K
Get TickerSpark's AI analysis on ZVSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 11, 25 | Cashmere Karen A. | other | 48,100 |
| Jul 11, 25 | Freitag Gregory Gene | other | 11,066 |
| Jul 11, 25 | Glover Stephen C. | other | 136,900 |
| Jul 11, 25 | Finizio Robert G | other | 11,066 |
| Jul 11, 25 | Wolfe Peter | other | 60,100 |
| Jul 11, 25 | Guzman Pablo A. | other | 48,900 |
| Jul 11, 25 | Park Min-Chul | other | 11,066 |
| Jul 11, 25 | SAPIRSTEIN JAMES | other | 11,066 |
| May 24, 23 | Cashmere Karen A. | other | 572 |
| May 24, 23 | Wolfe Peter | other | 715 |
Our ZVSA coverage
Recent articles, reports, and earnings notes.
No research on ZVSA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZVSA report →Similar companies
Peers in the same neighborhood.